Top Markets
Coin of the day
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Classement en actions #25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Prix de l'action
$0.74834668
Capitalisation boursière
$45.86M
Changement (1 jour)
-0.15%
Changement (1 an)
-6.28%
Pays
SE
Échange Mendus AB (publ) (IMMU)

Catégorie

Historique du rendement du dividende pour Mendus AB (publ) (IMMU)
Le rendement du dividende (TTM) de Mendus AB (publ) (symbole boursier : IMMU) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Mendus AB (publ) (IMMU) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US